REGN AI Stock Analysis – Buy, Hold, or Avoid?
Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron (REGN) offers a compelling long-term investment case, combining strong fundamentals, robust pipeline, and solid financial health with a fair valuation and moderate risk profile. While short-term technicals suggest consolidation and some caution, the medium- and long-term outlooks are supported by ongoing innovation, resilient earnings, and multiple growth catalysts. Investors with a 6-24 month horizon are likely to benefit most, while short-term traders should await a technical breakout or entry near support.
Fundamentals
Regeneron Pharmaceuticals exhibits robust fundamentals, with consistent revenue and EPS growth, strong profitability, and a solid pattern of earnings beats. The company's diverse biopharma portfolio, superior innovation, and consistent execution position it well for continued resilience in an evolving healthcare landscape. However, recent quarters have seen margin compression and slower sequential growth momentum.
Financial Highlights
- Revenue
- Net Income
- Net Margin (%)
Revenue
19.04% YoY
Q1 2026
Net Income
-10.08% YoY
Q1 2026
Net Margin
Q1 2026
Growth Metrics
Revenue Growth YoY
Latest Quarter: Q1 2026
Net Income Growth YoY
Latest Quarter: Q1 2026
Revenue Per Share Growth YoY
Latest Quarter: Q1 2026
EPS Growth YoY
Latest Quarter: Q1 2026
Book Value Per Share Growth YoY
Latest Quarter: Q1 2026
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.6B | 3.9B | 3.8B | 3.7B | 3.0B | 3.8B | 3.7B | 3.5B |
| Revenue Growth YoY | +19.04% | +2.51% | +0.90% | +3.62% | -3.70% | +10.33% | +10.65% | +12.32% |
| Net Income | 727.2M | 844.6M | 1.5B | 1.4B | 808.7M | 917.7M | 1.3B | 1.4B |
| Net Income Growth YoY | -10.08% | -7.97% | +8.91% | -2.84% | +12.01% | -20.86% | +33.02% | +47.90% |
| EPS | $6.99 | $8.21 | $14.09 | $13.24 | $7.58 | $8.53 | $12.40 | $13.25 |
| EPS Growth YoY | -7.78% | -3.75% | +13.63% | -0.08% | +13.13% | -21.60% | +30.80% | +46.41% |
Profitability Metrics
Technical Analysis
REGN is currently in a technical consolidation phase within a broader uptrend, with price trading below the 50 SMA but above the 200 SMA, indicating mixed short-term momentum but overall bullishness. The ADX suggests a strong trend presence, supporting potential for continuation toward prior highs. Momentum indicators like RSI are neutral, suggesting no extreme overbought or oversold conditions.
No extreme reading
Mixed signals
Strong trend active
Watching for cross
Key Technical Values
Price with Moving Averages
50-day, 150-day and 200-day simple moving averages
Relative Strength Index
Momentum oscillator measuring speed and magnitude of price changes
RSI (14)
Earnings
Regeneron Pharmaceuticals exhibits robust fundamentals, with consistent revenue and EPS growth, strong profitability, and a solid pattern of earnings beats. The company's diverse biopharma portfolio, superior innovation, and consistent execution position it well for continued resilience in an evolving healthcare landscape. However, recent quarters have seen margin compression and slower sequential growth momentum.
Latest Earnings
Q1 2026 Earnings (Mar 31, 2026)
Earnings Per Share (EPS)
Actual
$9.47
Estimated
$8.91
Surprise
+$0.56
Surprise %
+6.29%
Revenue
Actual
$3.61B
Estimated
$3.48B
Surprise
+$124.87M
Surprise %
+3.59%
Historical Earnings
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Earnings Per Share | ||||||||
| EPS (Actual) | $9.47 | $11.44 | $11.83 | $12.89 | $8.22 | $12.07 | $12.46 | $11.56 |
| EPS (Estimated) | $8.91 | $10.74 | $9.65 | $8.43 | $8.62 | $11.21 | $11.69 | $10.61 |
| EPS Surprise | +$0.56 | +$0.70 | +$2.18 | +$4.46 | -$0.40 | +$0.86 | +$0.77 | +$0.95 |
| % Diff | +6.3% | +6.5% | +22.6% | +52.9% | -4.6% | +7.7% | +6.6% | +9.0% |
| Revenue | ||||||||
| Revenue (Actual) | $3.61B | $3.88B | $3.75B | $3.68B | $3.03B | $3.79B | $3.72B | $3.55B |
| Revenue (Estimated) | $3.48B | $3.81B | $3.59B | $3.29B | $3.25B | $3.74B | $3.67B | $3.38B |
| Revenue Surprise | +$124.87M | +$73.55M | +$162.14M | +$387.47M | -$219.33M | +$46.96M | +$45.9M | +$163.59M |
| % Diff | +3.6% | +1.9% | +4.5% | +11.8% | -6.8% | +1.3% | +1.2% | +4.8% |
Valuation
Regeneron Pharmaceuticals currently trades at a valuation that appears attractive relative to its biotech peers, supported by solid financial health, consistent revenue growth, and a robust drug pipeline. Analyst consensus is bullish with a notable upside potential based on price targets that are well above the current market price.
Valuation Metrics
Price to Earnings
TTM
Price to Sales
TTM
Price to Book
TTM
Enterprise Value to EBITDA
TTM
Enterprise Value to Revenue
TTM
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Price to Earnings | 27.62 | 23.51 | 9.98 | 9.91 | 20.92 | 20.94 | 21.19 | 19.94 |
| Price to Sales | 22.29 | 20.45 | 15.52 | 15.01 | 22.34 | 20.28 | 30.54 | 32.21 |
| Price to Book | 2.56 | 2.54 | 1.88 | 1.84 | 2.30 | 2.62 | 3.88 | 4.05 |
| Enterprise Value to EBITDA | 82.81 | 65.80 | 30.46 | 33.72 | 64.66 | 70.39 | 70.21 | 65.23 |
| Enterprise Value to Revenue | 22.22 | 20.34 | 15.57 | 15.20 | 22.22 | 20.34 | 30.73 | 32.43 |
Sentiment & Analyst Ratings
Regeneron Pharmaceuticals (REGN) shows a moderately positive market sentiment supported by strong Q1 2026 earnings, FDA approval of a novel gene therapy, and a significant $3 billion share buyback program. While analysts maintain a consensus buy rating with price targets implying 25-40% upside, recent earnings price reactions and increased short interest suggest some investor caution. Social media sentiment remains generally bullish but mixed with concerns about income decline and competitive pressures.
Analyst Recommendations
Risk Assessment
Regeneron Pharmaceuticals maintains a financially strong position with robust liquidity and minimal leverage, underpinning its ability to fund ongoing R&D and absorb sector challenges. However, the company faces significant risks from competitive pressures on its flagship product Eylea, regulatory uncertainties, and potential pipeline setbacks typical of the biotechnology sector. Overall, while the firm’s balance sheet strength and innovative capabilities reduce financial risk, evolving industry headwinds temper the investment outlook.
Liquidity & Solvency
Current Ratio
Latest Quarter: Q1 2026
Quick Ratio
Latest Quarter: Q1 2026
Debt-to-Equity
Latest Quarter: Q1 2026
Debt-to-Assets
Latest Quarter: Q1 2026
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Liquidity Metrics | ||||||||
| Current Ratio | 3.57 | 4.13 | 4.06 | 4.60 | 4.93 | 4.73 | 5.28 | 5.44 |
| Quick Ratio | 2.96 | 3.39 | 3.33 | 3.72 | 4.03 | 3.95 | 4.46 | 4.62 |
| Solvency Metrics | ||||||||
| Debt-to-Equity | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.10 |
| Debt-to-Assets | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 |
Liquidity Assessment
Current Ratio: 3.57(Strong)
Quick Ratio: 2.96(Strong)
The company has strong liquidity with sufficient short-term assets to cover liabilities.
Solvency Assessment
Debt-to-Equity: 0.09(Low)
Debt-to-Assets: 0.07(Low)
The company has conservative debt levels, indicating low financial risk and strong long-term solvency.
Frequently Asked Questions about REGN
AI Answers: Common Questions About REGN
Get AI-powered answers to the questions investors ask most about Regeneron Pharmaceuticals, Inc.
Regeneron is a good buy for medium- and long-term investors, trading at a P/E of 17.44 (below peer average) and well below analyst price targets (implying 25-40% upside). The current price of $714.89 is near the lower end of its recent range, offering an attractive entry for those willing to tolerate short-term volatility.
There is no strong reason to sell REGN now unless your thesis has changed or you need to reduce exposure; fundamentals remain robust, and while technicals are neutral, the long-term outlook is positive. Only consider selling if the price breaks below major support ($687) or if upcoming catalysts disappoint.
The biggest risks are Eylea's revenue decline from biosimilar competition (with patent expiration looming), regulatory or clinical pipeline setbacks, and recent margin compression from higher R&D/SG&A. However, Regeneron's current ratio of 3.57 and debt-to-equity of 0.09 indicate strong financial resilience.
Short-term resistance is at $749 (50 SMA) and $821 (52-week high), with support at $687 (200 SMA). Analyst price targets imply 25-40% upside from current levels, suggesting a medium-term target range of $900-$1,000 if growth catalysts materialize.
REGN is fairly valued to slightly undervalued, with a P/E of 17.44 and EV/EBITDA below sector averages. Strong cash flow, low debt, and ongoing revenue growth justify its current multiples, especially given the pipeline and analyst upside.
Regeneron's fundamentals are strong: annual revenue and EPS growth (10% and 8.2% respectively), gross margin above 81%, and a diversified, innovation-driven product portfolio. The balance sheet is robust, with high liquidity and minimal leverage.
Technically, REGN is consolidating between $687 and $749, with price below the 50 SMA but above the 200 SMA. RSI is neutral (~44), so no immediate reversal is signaled; traders should wait for a breakout above $749 or a retest of support before entering.
Key catalysts include upcoming pipeline readouts, further FDA approvals (notably for Otarmeni and Dupixent), execution of the $3B share buyback, and quarterly earnings. Watch for regulatory news and competitive developments in Eylea and immunology franchises.
Want a Personalized Answer?
Get AI-powered insights tailored to your risk tolerance and investment goals.